Oculis biopharmaceutical company has announced the second Phase 3 OPTIMIZE-2 trial for OCS-01 once-daily eye drops for the treatment of post-op inflammation following cataract surgery.
OCS-01 is the first once-daily topical, preservative-free corticosteroid. In the second Phase 3 OPTIMIZE-2 trial, patients will be treated with OCS-01 once a day after cataract surgery for two weeks. This second trial hopes to have the same results as the first trial which had a positive percentage of patients who were inflammation free at Day 15 and had zero pain at Day 4 versus the traditional post-op therapies.
Despite cataract surgery only involving a tiny incision, it still causes inflammation in the cornea, anterior chamber, and iris. The current post-op therapy utilizes topical steroids, antibiotics and NSAID and can require multiple drops a day for several weeks and often results in compliance issues.
OCS-01 works by increasing the residence time on the surface of the eye, which means less frequent administration for front-of-the eye and the drug moving from the surface of the eye to back segment of the eye. Ophthalmologists are excited about OCS-01 becoming an approved therapy for pain and inflammation after cataract surgery especially for patients who are at a higher risk of developing complications because of existing inflammation.
